HPV Vaccination in Schools: Who Made the Vaccine — and What Happened to the Promise of Cancer Protection?

On 28 April 2026, Berlin’s senator for science, health and care, Ina Czyborra (SPD), issued a press release titled “Senate weighs options to improve HPV vaccination coverage”. Core sentence: “HPV can cause cancer — and we have it in our hands to protect ourselves effectively against it.” The plan: information letters to parents of pupils in grades 4 through 10, integrating vaccination into the new U10 child-health check-up, and reminder systems where check-ups are missed.

One day later, on 29 April 2026, Germany’s tabloid BILD turned that into the headline: “Public-health doctors should vaccinate against sex viruses in schools!” “HPV” (Human Papillomavirus) became “sex viruses”. A routine inter-ministerial Senate consultation became boulevard.

The push itself isn’t new. Klaus Überla, chair of Germany’s Standing Vaccination Committee (STIKO), called for “new ways” to raise the HPV vaccination rate as far back as 25 March 2024 in an interview with the Funke newspaper group. He described tolerability as “outstanding” and the vaccine as “highly effective”. School vaccinations, he said, would “save lives in the long run”.

These three voices — senator, STIKO chair, BILD — have for weeks formed a coordinated push for HPV vaccination in schools. What they leave out is the complexity of the data, of the products, and of the people who developed them. This post fills in five points.

1. Who Made Gardasil? One Career, Three Vaccines

#

The HPV vaccine Gardasil was developed at Merck under the R&D leadership of Kathrin Jansen. Jansen joined Merck in 1992 and pushed the HPV project through against substantial internal opposition. Merck’s finance division classified the project as “worth less than nothing” and reduced it on the company’s balance sheet. Other researchers considered the approach hopeless — citing as evidence that no herpes vaccine (a related sexually transmitted virus family) had ever worked. In a documented key scene, a senior researcher cornered Jansen in a hallway after a meeting and yelled at her; she reported the incident to her superiors.

Jansen prevailed. In 2002, an NEJM study showed 100 % efficacy against HPV-16 infection. Gardasil received FDA approval in 2006 based on trials involving 21,000 girls and women.

In 2004, Jansen left Merck. She moved to VaxGen (Chief Scientific Officer), then in 2006 to Wyeth — which Pfizer acquired in 2009. At Wyeth/Pfizer, she developed the pneumococcal vaccine Prevnar-13. During the pandemic in 2020, on the Pfizer side she led development of the Pfizer-BioNTech COVID-19 vaccine (US Emergency Use Authorization on 11 December 2020). In April 2022 she announced retirement.

Three of the most publicly contested vaccines of the past twenty years — Gardasil 2006, Prevnar-13 2010, Comirnaty 2020 — fall under the R&D leadership of one and the same person. The 2020 STAT News characterization read: “a scientist with a history of defying skeptics — and getting results.” That isn’t PR; it’s the verifiable career line. What structural lesson follows from it is a separate question. But anyone speaking about HPV school vaccinations and framing Gardasil as a pure cancer-prevention tool ought at least to know the pipeline figure behind it.

2. What the Gardasil Trials Actually Measured

#

Berlin’s senator says: “HPV can cause cancer — and we have it in our hands.” The leap from “can cause” to “we have it in our hands” turns the product into a cancer-prevention tool. The licensing trials did not establish that in the form the political slogan implies.

The original Gardasil trials had as primary endpoints the reduction of HPV-16/18 infections and CIN2/CIN3 — so-called cervical intraepithelial neoplasias, that is, precursor lesions which over a 10- to 30-year window may progress to invasive cervical cancer, but do not necessarily do so. Reduction of cervical-cancer mortality was originally a surrogate inference, not a measured endpoint. Direct measurement would have been impossible at the 2006 licensing point because the cervical-cancer latency window far exceeds any feasible trial length.

By now, first endpoint-level data exists. A Swedish NEJM study (Lei et al. 2020) showed a substantial reduction of invasive cervical carcinomas during the observation window for women vaccinated before age 17. England reports 87 % efficacy against cervical cancer for vaccination at ages 12-13. These are real findings — but they only became available around 2020, fourteen years after market launch. Political communication between 2006 and 2020 made a promise that the data only began to partially redeem years later.

Methodologically this gap parallels the transmission question for the COVID vaccines in 2020/2021: what the trials measured (symptomatic disease) and what the political messaging promised (“the vaccine protects others”) were two different endpoints. This blog’s structural-analysis series has documented that bracket separately for Comirnaty.

3. Which Strains Does the Vaccine Cover — and What is Type Replacement?

#

There are over 200 known HPV types, of which roughly 14 are classified as high-risk oncogenic. The original quadrivalent Gardasil covered four types: HPV-6 and 11 (genital warts) and HPV-16 and 18 (together responsible for ~70 % of cervical cancers). Gardasil-9 (nonavalent, since 2014/15) additionally covers HPV-31, 33, 45, 52 and 58 — 9 of the ~14 oncogenic types, corresponding to roughly 90-95 % of cervical-cancer-associated strains observed so far.

The point routinely missing from political messaging: type replacement. A systematic review on the impact of HPV vaccines (most recently updated 2024, MDPI Viruses) documents that non-vaccine types become relatively more prevalent in vaccinated populations. An Italian study notes: the prevalence of all seven high-risk types covered by Gardasil-9 remained stable in the studied population — while the detection of non-vaccine HPV types and HPV-negative/unknown types increased. What this means long-term for carcinoma incidence is not settled — propagation of this shift occurs via sexual transmission into unvaccinated parts of the population as well.

So the vaccine does not protect “against HPV” as a blanket category; it protects against selected types. The ecological response of the unvaccinated types is research consensus, not conspiracy speculation.

4. Conization and Screening: the Workload Stays

#

For women with abnormal Pap results or a positive HPV test, conization (surgical removal of a tissue cone from the cervix) is a standard treatment for clearing precursor lesions. A practical question follows: does vaccination reduce the conization workload?

A 2025 study in Scientific Reports shows that vaccinated women have substantially higher HPV-clearance rates after conization (81.1 % versus 57.1 % in unvaccinated patients post-LEEP/conization). A 2024 US cohort study (n=83,352) shows a significant reduction in high-grade cervical lesions among vaccinated women.

But: the RKI itself confirms (as of 6 June 2025) that vaccinated women must continue to participate in cervical-cancer screening — the screening routine is not replaced. According to RKI data, at most 60 % of girls in Germany are fully vaccinated, many of them only after age 15 (with reduced efficacy). The aggregate societal screening workload thus remains substantially unchanged.

Saying “the vaccine protects against cancer” and at the same time “you still need to attend screening” amounts to two statements that don’t align with the political poster’s suggestion. They do align medically — but then the vaccine is one component alongside screening, not a closing chapter. That distinction belongs in the Senate’s parental information letter; otherwise it raises an expectation the product cannot structurally meet.

5. The Pharmacovigilance Record: Japan, Lawsuits, Whistleblowers

#

June 2013, Japan. Two months after HPV vaccination was integrated into Japan’s National Immunization Program, the health ministry MHLW suspended its “proactive recommendation” for the vaccine. Trigger: reports of severe neurological adverse events in young girls — involuntary movements, gait disturbance, chronic pain. Japanese TV networks reportedly aired the footage up to 80 times per day, according to industry-association statements. The advisory Vaccine Adverse Reactions Review Committee (VARRC) concluded that no causal connection could be established. Even so, the suspension of the proactive recommendation lasted more than eight years, until 2022. For a licensed vaccine in a G7 country, that is unprecedented.

In the United States, since 2024/2025 a wave of lawsuits has been moving against Merck alleging the company concealed Gardasil risks (“Merck Faces Claims of Concealing Risks”, multidistrict litigation). A whistleblower account from within Merck’s research environment alleges that the company ignored evidence of a link between Gardasil and autoimmune disease. These proceedings are not concluded — and no judgment has been issued. But they are real, pending, and verifiable.

Anyone presenting Gardasil’s safety record as a closed book skips over this. The Japanese suspension was never a topic of meaningful discussion in Germany, even though it was one of the longest of its kind.

Conclusion: Information or Administrative Campaign?

#

Five questions on which it will be decided whether Berlin’s initiative becomes information or administrative campaign:

• Will parents be told that Gardasil-9 does not cover all oncogenic HPV types?
• Will it be explained that direct cervical-cancer reduction has only been measurable since approximately 2020 in selected study populations, fourteen years after market launch?
• Will type replacement be named methodically?
• Will it be stated that screening obligations remain in place for vaccinated women?
• Will Japan be mentioned — will the ongoing US lawsuits and whistleblower proceedings be mentioned?

When the senator says “we have it in our hands” and BILD turns that one day later into “sex-viruses school vaccination”, that is not an information architecture. That is push campaign with a tabloid amplifier. Push campaigns produce, on a timescale of years, distrust — precisely because they reduce away complexity that resurfaces later.

A government that addresses grades 4 through 10 with boulevard language, closing-chapter promises, and a missing word on the pharmacovigilance record has decided in favor of administration, not information. The parents who notice this and ask questions are not the problem. They are the symptom of an authority deciding which side of the campaign it wants to stand on.

Methodology note: Falsification conditions, source policy and pre-commit discipline are explained systematically on the Methodology page — and apply to every individual finding in this post. Source apparatus follows below.

Sources

#

1. Senate Department for Science, Health and Care (Berlin), press release of 28.04.2026: “Senat berät Handlungsoptionen zur Verbesserung des HPV-Impfschutzes” (in German). https://www.berlin.de/rbmskzl/aktuelles/pressemitteilungen/2026/pressemitteilung.1665639.php
2. BILD, headline of 29.04.2026: “Amtsärzte sollen in Schulen gegen Sex-Viren impfen!” (Symbolbild picture alliance/M.i.S.-Sportpressefoto)
3. Deutsches Ärzteblatt, 25.03.2024: “STIKO-Chef für Schulimpfungen zur Steigerung der HPV-Impfquote unter Kindern” (in German). Interview with the Funke newspaper group. https://www.aerzteblatt.de/news/stiko-chef-fuer-schulimpfungen-zur-steigerung-der-hpv-impfquote-unter-kindern-628c7ce6-8150-47ee-b58d-4f7f861d5f34
4. Wikipedia: Kathrin Jansen — career chronology. https://en.wikipedia.org/wiki/Kathrin_Jansen
5. STAT News, 24.08.2020: “In the race for a Covid-19 vaccine, Pfizer turns to a scientist with a history of defying skeptics — and getting results”. https://www.statnews.com/2020/08/24/pfizer-edge-in-the-race-for-a-covid-19-vaccine-could-be-a-scientist-with-two-best-sellers-to-her-credit/
6. Fast Company: “Meet Kathrin Jansen, the woman leading Pfizer’s COVID-19 vaccine effort”. https://www.fastcompany.com/90573460/kathrin-jansen-pfizer-covid-19-vaccine-scientist
7. Lei J., Ploner A., Elfström K.M., Wang J., Roth A., Fang F., Sundström K., Dillner J., Sparén P. (2020): “HPV Vaccination and the Risk of Invasive Cervical Cancer”. New England Journal of Medicine 383(14):1340-1348. https://www.nejm.org/doi/full/10.1056/NEJMoa1917338
8. RKI, FAQ HPV vaccination recommendation (as of 6.6.2025, in German): https://www.rki.de/SharedDocs/FAQs/DE/Impfen/HPV/FAQ-Liste_HPV_Impfempfehlung.html
9. RKI, FAQ HPV vaccination implementation (as of 28.4.2025, in German): screening note for the vaccinated. https://www.rki.de/SharedDocs/FAQs/DE/Impfen/HPV/FAQ-Liste_HPV-Impfung-Durchfuehrung.html
10. “Update on Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology” (2024), MDPI Viruses 16(8):1245 — documents type replacement. https://www.mdpi.com/1999-4915/16/8/1245
11. Effect of vaccination against HPV in HPV-positive patients (2025), Scientific Reports — comparative LEEP/conization HPV clearance. https://www.nature.com/articles/s41598-025-92861-5
12. “HPV vaccination in Japan” — Wikipedia overview of the 2013-2022 suspension with primary-source references. https://en.wikipedia.org/wiki/HPV_vaccination_in_Japan
13. Expert Institute (2025): “Gardasil Vaccine Lawsuit: Merck Faces Claims of Concealing Risks”. Overview of the ongoing US litigation. https://www.expertinstitute.com/resources/insights/merck-faces-claims-of-withholding-information-about-gardasil-vaccine-risk/
14. Pfizer Bio: Kathrin Jansen (Pfizer press team): https://www.pfizer.com/people/medical-experts/vaccinations/kathrin_jansen-phd

Source of the BILD headline: The wording “Amtsärzte sollen in Schulen gegen Sex-Viren impfen!” is documented via an X repost (@dokhollidays / OrthopaeDenker, 29.04.2026); the direct BILD tweet thread was not findable. The temporal and substantive link to Czyborra’s press release of 28.04.2026 is unambiguous — the leap from “HPV” to “sex viruses” is tabloid translation, not Senate language.